{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:31:19Z","timestamp":1791973879024,"version":"4.4.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mdconsult.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.psc.2014.05.006","type":"journal-article","created":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T03:45:21Z","timestamp":1406173521000},"page":"375-391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":176,"title":["Pharmacological Treatment of Obsessive-Compulsive Disorder"],"prefix":"10.1016","volume":"37","author":[{"given":"Christopher","family":"Pittenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.psc.2014.05.006_bib2","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","first-page":"947","author":"American Psychiatric Association","year":"2013"},{"issue":"Suppl 7","key":"10.1016\/j.psc.2014.05.006_bib3","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.psc.2014.05.006_bib4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archpsyc.1983.04390010015002","article-title":"Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline","volume":"40","author":"Insel","year":"1983","journal-title":"Arch Gen Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib5","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","article-title":"Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.psc.2014.05.006_bib6","article-title":"Obsessive compulsive disorder","volume":"2012","author":"Soomro","year":"2012","journal-title":"Clin Evid (Online)"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001765.pub3","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","author":"Soomro","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.psc.2014.05.006_bib8","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.psc.2014.05.006_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1192\/bjp.174.4.297","article-title":"Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials","volume":"174","author":"Bollini","year":"1999","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.psc.2014.05.006_bib10","unstructured":"FDA. FDA drug safety comunications: revised recommendations for celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. 2012 [cited January 14, 2014]."},{"issue":"1421","key":"10.1016\/j.psc.2014.05.006_bib11","first-page":"59","article-title":"Citalopram, escitalopram, and the QT interval","volume":"55","year":"2013","journal-title":"Med Lett Drugs Ther"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib12","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1176\/appi.ajp.2013.13081052","article-title":"Safety of high-dosage citalopram","volume":"171","author":"Zivin","year":"2014","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004714-200206000-00012","article-title":"Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder","volume":"22","author":"Ackerman","year":"2002","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1017\/S1092852900014024","article-title":"Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients","volume":"13","author":"Marazziti","year":"2008","journal-title":"CNS Spectr"},{"issue":"6","key":"10.1016\/j.psc.2014.05.006_bib15","first-page":"257","article-title":"Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data","volume":"57","author":"Szegedi","year":"1996","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"6\u20137","key":"10.1016\/j.psc.2014.05.006_bib16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.euroneuro.2006.11.005","article-title":"Escitalopram prevents relapse of obsessive-compulsive disorder","volume":"17","author":"Fineberg","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1\u20133","key":"10.1016\/j.psc.2014.05.006_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jad.2009.06.021","article-title":"Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis","volume":"123","author":"Donovan","year":"2010","journal-title":"J\u00a0Affect Disord"},{"issue":"4","key":"10.1016\/j.psc.2014.05.006_bib18","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4088\/JCP.v67n0411","article-title":"Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review","volume":"67","author":"Dell'Osso","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2014.05.006_bib19","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4088\/JCP.v64n0508","article-title":"Venlafaxine in treatment-resistant obsessive-compulsive disorder","volume":"64","author":"Hollander","year":"2003","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib20","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.v65n0106","article-title":"A\u00a0double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder","volume":"65","author":"Denys","year":"2004","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.psc.2014.05.006_bib21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A\u00a0systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1017\/S1461145712000740","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"16","author":"Dold","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib23","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib24","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.psc.2014.05.006_bib25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/ajmg.b.32137","article-title":"Meta-analysis of association between obsessive-compulsive disorder and the 3' region of neuronal glutamate transporter gene SLC1A1","volume":"162B","author":"Stewart","year":"2013","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopsych.2012.06.023","article-title":"A\u00a0critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder","volume":"73","author":"Brennan","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2014.05.006_bib27","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2009.77","article-title":"Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder","volume":"34","author":"Bhattacharyya","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"10.1016\/j.psc.2014.05.006_bib28","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/sj.npp.1300733","article-title":"Glutamatergic dysfunction in OCD","volume":"30","author":"Chakrabarty","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.psc.2014.05.006_bib29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.pnpbp.2006.04.013","article-title":"Memantine augmentation for refractory obsessive-compulsive disorder","volume":"30","author":"Pasquini","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib30","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1176\/appi.ajp.162.11.2191-a","article-title":"Memantine for treatment-resistant OCD","volume":"162","author":"Poyurovsky","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A\u00a0single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart","year":"2010","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib32","first-page":"81","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"10.1016\/j.psc.2014.05.006_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J\u00a0Psychiatr Res"},{"issue":"4","key":"10.1016\/j.psc.2014.05.006_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"228","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.psc.2014.05.006_bib35","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpsychires.2008.10.007","article-title":"Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults","volume":"43","author":"Greenberg","year":"2009","journal-title":"J\u00a0Psychiatr Res"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/JCP.0b013e3182189878","article-title":"Sarcosine therapy for obsessive compulsive disorder: a prospective, open-label study","volume":"31","author":"Wu","year":"2011","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.psc.2014.05.006_bib37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.biopsych.2013.03.026","article-title":"Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond","volume":"73","author":"Krystal","year":"2013","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2014.05.006_bib38","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib39","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.psc.2014.05.006_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/JCP.0b013e3181727548","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up","volume":"28","author":"Pittenger","year":"2008","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.psc.2014.05.006_bib42","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2165\/00023210-200822090-00004","article-title":"Riluzole in the treatment of mood and anxiety disorders","volume":"22","author":"Pittenger","year":"2008","journal-title":"CNS Drugs"},{"issue":"5","key":"10.1016\/j.psc.2014.05.006_bib43","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","article-title":"Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Berlin","year":"2011","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1092852912000065","article-title":"Topiramate augmentation in resistant OCD: a double-blind placebo-controlled clinical trial","volume":"15","author":"Mowla","year":"2010","journal-title":"CNS Spectr"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib45","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/j.1440-1614.2000.0751c.x","article-title":"Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder","volume":"34","author":"Kumar","year":"2000","journal-title":"Aust N Z J Psychiatry"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib46","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study","volume":"26","author":"Bruno","year":"2012","journal-title":"J\u00a0Psychopharmacol"},{"issue":"2","key":"10.1016\/j.psc.2014.05.006_bib47","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.psc.2014.05.006_bib48","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"Suppl 4","key":"10.1016\/j.psc.2014.05.006_bib49","first-page":"19","article-title":"The pharmacologic profile of mirtazapine","volume":"57","author":"de Boer","year":"1996","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2014.05.006_bib50","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4088\/JCP.v63n0908","article-title":"Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial","volume":"63","author":"Pallanti","year":"2002","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.psc.2014.05.006_bib51","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.140.9.1219","article-title":"Naloxone administration in obsessive-compulsive disorder: report of two cases","volume":"140","author":"Insel","year":"1983","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/JCP.v66n0312","article-title":"Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder","volume":"66","author":"Koran","year":"2005","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.psc.2014.05.006_bib53","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1520-6394(1997)6:4<170::AID-DA7>3.0.CO;2-G","article-title":"Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder","volume":"6","author":"Shapira","year":"1997","journal-title":"Depress Anxiety"},{"issue":"12","key":"10.1016\/j.psc.2014.05.006_bib54","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2165\/11530240-000000000-00000","article-title":"Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study","volume":"23","author":"Pallanti","year":"2009","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.euroneuro.2013.12.003","article-title":"Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation","volume":"24","author":"Pallanti","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"10","key":"10.1016\/j.psc.2014.05.006_bib56","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/11635850-000000000-00000","article-title":"Granisetron adjunct to fluvoxamine for moderate to severe obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Askari","year":"2012","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.psc.2014.05.006_bib57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hup.1145","article-title":"A\u00a0double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder","volume":"25","author":"Soltani","year":"2010","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.psc.2014.05.006_bib58","unstructured":"Transcept Pharmaceuticals, I. Transcept Pharmaceuticals announces that a Phase 2 clinical trial of TO\u00a0= 2061 as adjunctive therapy for obsessive-compulsive disorder did not meet primary endpoint. 2012. Available at: http:\/\/ir.transcept.com\/releasedetail.cfm?ReleaseID=728327. Accessed February 17, 2014."},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib59","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4088\/JCP.08m04605","article-title":"Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"70","author":"Koran","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib60","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jad.2011.04.051","article-title":"Complementary medicine, self-help, and lifestyle interventions for obsessive compulsive disorder (OCD) and the OCD spectrum: a systematic review","volume":"138","author":"Sarris","year":"2012","journal-title":"J\u00a0Affect Disord"},{"issue":"4","key":"10.1016\/j.psc.2014.05.006_bib61","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pnpbp.2011.02.011","article-title":"Nutraceuticals in the treatment of obsessive compulsive disorder (OCD): a review of mechanistic and clinical evidence","volume":"35","author":"Camfield","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.psc.2014.05.006_bib62","first-page":"17","article-title":"Over-the-counter supplements in the treatment of obsessive compulsive disorder: practical considerations and evidence","volume":"Summer 2013","author":"Kichuk","year":"2013","journal-title":"Newsletter of the International OCD Foundation"},{"issue":"9","key":"10.1016\/j.psc.2014.05.006_bib63","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1176\/ajp.153.9.1219","article-title":"Inositol treatment of obsessive-compulsive disorder","volume":"153","author":"Fux","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psc.2014.05.006_bib64","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145799001546","article-title":"Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study","volume":"2","author":"Fux","year":"1999","journal-title":"Int J Neuropsychopharmacol"},{"issue":"16","key":"10.1016\/j.psc.2014.05.006_bib65","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","article-title":"Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial","volume":"292","author":"Pediatric OCD Treatment Study (POTS) Team","year":"2004","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib66","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1001\/jama.2011.1344","article-title":"Cognitive behavior therapy augmentation of pharmacotherapy in pediatric obsessive-compulsive disorder: the Pediatric OCD Treatment Study II (POTS II) randomized controlled trial","volume":"306","author":"Franklin","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib68","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/npp.2010.88","article-title":"Glutamate receptors in extinction and extinction-based therapies for psychiatric illness","volume":"36","author":"Myers","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"13\u201314","key":"10.1016\/j.psc.2014.05.006_bib69","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.drudis.2009.05.002","article-title":"Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia","volume":"14","author":"Krystal","year":"2009","journal-title":"Drug Discov Today"},{"issue":"6","key":"10.1016\/j.psc.2014.05.006_bib70","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1523\/JNEUROSCI.22-06-02343.2002","article-title":"Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats","volume":"22","author":"Walker","year":"2002","journal-title":"J\u00a0Neurosci"},{"issue":"11","key":"10.1016\/j.psc.2014.05.006_bib71","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","article-title":"Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"10.1016\/j.psc.2014.05.006_bib72","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.biopsych.2008.01.012","article-title":"A\u00a0meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy","volume":"63","author":"Norberg","year":"2008","journal-title":"Biol Psychiatry"},{"issue":"36","key":"10.1016\/j.psc.2014.05.006_bib73","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.2174\/138161212803523617","article-title":"Genetics and personalized medicine in antidepressant treatment","volume":"18","author":"Gvozdic","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.psc.2014.05.006_bib74","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/mp.2008.116","article-title":"Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder","volume":"15","author":"Kato","year":"2010","journal-title":"Mol Psychiatry"},{"issue":"1","key":"10.1016\/j.psc.2014.05.006_bib75","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/pgs.11.133","article-title":"Pharmacogenetics of obsessive-compulsive disorders","volume":"13","author":"Brandl","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.psc.2014.05.006_bib76","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/tpj.2013.12","article-title":"Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder","volume":"14","author":"Brandl","year":"2014","journal-title":"Pharmacogenomics J"}],"container-title":["Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X14000549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0193953X14000549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T03:59:37Z","timestamp":1565668777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0193953X14000549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0193953X14000549"],"URL":"https:\/\/doi.org\/10.1016\/j.psc.2014.05.006","relation":{},"ISSN":["0193-953X"],"issn-type":[{"value":"0193-953X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological Treatment of Obsessive-Compulsive Disorder","name":"articletitle","label":"Article Title"},{"value":"Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psc.2014.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}